COVID-19:欧盟,伦贝西比供应合同:需要审核吗?
-在WHO临床试验中几乎未见效果-
伦地比尔:
世卫组织试验结果:
在世界卫生组织(WHO)的一项临床试验(临床研究)中,美国Gilliad Sciences抗病毒药物“ Remdecibir”显示出“对降低死亡率几乎没有影响的结果”。
与欧盟的供应合同:
10月8日,欧盟与Gilliad代表27个成员国和包括英国在内的10个伙伴国家签署了供应协议。
需要审查:
欧盟(EU)与Gilliado签署了10亿欧元(12亿美元)的供应合同。
有一个“需要审查的观点”。
欧洲药品管理局(EMA):Janice Natosis
欧盟委员会
解释了欧盟为何加快与吉利亚德达成协议,
根据WHO的试验结果
合同需要审查。
说过。
欧盟发言人:
他拒绝评论“与吉列德签订合同时,欧盟是否已获悉世卫组织的审判结果?”
他还拒绝评论“是否重新谈判与吉利亚德所同意的价格”。
新闻周刊日本版
https://www.newsweekjapan.jp/stories/world/2020/10/euwho.php
Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury® (remdesivir)
FOSTER CITY, Calif.–(BUSINESS WIRE)–
Gilead Sciences (Nasdaq: GILD) and the European Commission
today signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir),
the first antiviral drug proven to be effective for the treatment of COVID-19 in the European Union (EU).
First COVID-19 treatment recommended for EU authorisation
Remdesivir
is the first medicine against COVID-19 to be recommended for authorisation in the EU.
Data on remdesivir
were assessed in an exceptionally short timeframe through a rolling review procedure,
an approach used by EMA during public health emergencies to assess data as they become available.
European Medicines Agency
https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation
Remdesivir price curbs in India make COVID-19 treatment more affordable: GlobalData – Express Pharma